Visual Impairment News and Research RSS Feed - Visual Impairment News and Research

The definition of vision impairment by the Centers for Disease Control and Prevention (CDC) says a visually impaired person’s eyesight cannot be corrected to a “normal level”.
Prosthetic retina could help counter the effects of AMD and related vision disorders

Prosthetic retina could help counter the effects of AMD and related vision disorders

The loss of eyesight, often caused by retinal degeneration, is a life-altering health issue for many people, especially as they age. [More]
Leading causes of blindness can be detected by looking at how eyes respond to watching TV

Leading causes of blindness can be detected by looking at how eyes respond to watching TV

One of the leading causes of blindness worldwide could be detected by how our eyes respond to watching TV according to a new study from researchers at City University London. [More]
Endothelin gene expression linked to vision loss in premature babies

Endothelin gene expression linked to vision loss in premature babies

A gene known to play a major role in constricting blood vessels also appears to be a major player in the aberrant blood vessel growth that can destroy the vision of premature babies. [More]
VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare's Implantable Miniature Telescope gets FDA approval for treating end-stage AMD

VisionCare Ophthalmic Technologies, Inc., a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced the U.S. Food and Drug Administration approved the Implantable Miniature Telescope (by Dr. Isaac Lipshitz) for use in patients living with bilateral end-stage age-related macular degeneration who are age 65 or older. [More]
Health Canada approves Lucentis (ranibizumab) for myopic CNV

Health Canada approves Lucentis (ranibizumab) for myopic CNV

Novartis Pharmaceuticals Canada Inc. announced today that Lucentis (ranibizumab), the treatment for several major causes of vision loss, has been approved by Health Canada for the treatment of visual impairment due to choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV). [More]
Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Three-year safety data from INTREPID study of Oraya Therapy™ for wet age-related macular degeneration results announced

Oraya Therapeutics Inc. announced that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. [More]
Lifestyle factors modify vision impairment risk

Lifestyle factors modify vision impairment risk

Smoking, drinking alcohol and physical activity are modifiable behaviours that influence the risk of vision impairment, show findings from the Beaver Dam Eye Study. [More]
Central sclera thickening characterises dome-shaped macula

Central sclera thickening characterises dome-shaped macula

A dome-shaped macula appears to result from the relative thickening of the central macular sclera, researchers have found. [More]
Simple colour test could detect early onset of nAMD in the UK

Simple colour test could detect early onset of nAMD in the UK

A simple colour test that could detect the early onset of a condition which accounts for over half of visual impairment certifications in the UK is being researched by scientists at Aston University. [More]
Study examines ocular changes seen in astronauts to treat spaceflight-induced visual impairment

Study examines ocular changes seen in astronauts to treat spaceflight-induced visual impairment

To reduce and better treat spaceflight-induced visual impairment, University of Houston (UH) optometrists are collaborating on a NASA study that examines ocular changes seen in a number of astronauts. [More]
Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

The Perelman School of Medicine at the University of Pennsylvania has launched the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to build on its previous success developing novel therapies for the personalized diagnosis and treatment of retinal and ocular disorders. [More]

French Ministry of Health approves financial support for Second Sight Argus II Retinal Prosthesis System

Second Sight Medical Products Inc. today announces that the French Ministry of Health has officially approved financial support for the Argus II Retinal Prosthesis System. Through the Forfait Innovation scheme, the French Government will pay for the first wave of groundbreaking treatment for 36 patients with severe to total sight loss due to retinitis pigmentosa (RP) in France. [More]
Research: New ways to help visually impaired better navigate everyday life

Research: New ways to help visually impaired better navigate everyday life

Visual impairment comes in many forms, and it's on the rise in America. A University of Cincinnati experiment aimed at this diverse and growing population could spark development of advanced tools to help all the aging baby boomers, injured veterans, diabetics and white-cane-wielding pedestrians navigate the blurred edges of everyday life. [More]
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema. [More]

Hearing problems reduce active participation of older people in various events

Vision and hearing problems reduce the active participation of older people in various events and activities. This was observed in two studies carried out by the Gerontology Research Center. [More]
Early stage AMD can occur much earlier than previously thought

Early stage AMD can occur much earlier than previously thought

It is widely accepted that age-related macular degeneration (AMD) is the most common cause of visual impairment and blindness in industrialized countries. [More]
Study shows correlation between education and nearsightedness

Study shows correlation between education and nearsightedness

Education and behavior have a greater impact on the development of nearsightedness than do genetic factors: With each school year completed, a person becomes more nearsighted. [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
LA BioMed researchers launch new project to improve diabetes management

LA BioMed researchers launch new project to improve diabetes management

Managing diabetes is a year-round challenge for anyone living with the disease. The challenge is even greater for underserved and uninsured people who often don't have easy access to the care they need to manage their diabetes. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]